Home » Newsletters » BioWorld Science

BioWorld Science

July 23, 2008

View Archived Issues

New antiinfective agents disclosed in recent Novartis patent

Recent patents describe new treatment options for cardiovascular diseases

Combined radiation therapy with GMX-1777 may be useful in head and neck cancer

Gamida-Cell enters agreement with Amgen for use of cytokines in manufacture of StemEx

Pain Therapeutics reports results from phase I clinical trial of melanin-binding antibody

Alnylam grants InterfeRx license to Calando for RNAi therapeutics

2008 highlights at Lorus Therapeutics

Gilead Sciences offers Q2 overview

Antisense presents an update on the company's activities

Combretastatin A4 safe and effective in patients with anaplastic thyroid cancer

Novel analgesic agents reported in recent patent literature

Rituximab plus IVIG effective in desensitization for kidney transplantation

Nanoparticle-mediated drug delivery suppresses metastasis in murine cancer models

GeneNews launches blood-based molecular colorectal cancer test, ColonSentry

BioMarin and Summit collaborate on Duchenne muscular dystrophy program

Living Cell Technologies reports clinical benefit with DiabeCell in diabetes trial

Opexa reports results from phase I/II extension study with Tovaxin in MS

NicOx completes enrollment in 2 phase I trials of naproxcinod in hypertensive OA patients

Cenix and Regulus enter research agreement for miRNA-targeted drug discovery

Cell Therapeutics to meet with FDA in September 2008 to discuss sBLA for Zevalin

Roche to acquire Mirus for USD 125 million

Amorfix and UBC enter Alzheimer's research collaboration based on SOD1 protein

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.